Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Table 5

The relationship between SALL4 expression and tumor recurrence.

Tumor recurrence	Number of each group		𝑃
	Low SALL4 group	High SALL4 group
	(<130.43 pg/mL)	(≥130.43 pg/mL)
Absent	18	10	0.016
Present	9	19